• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CalciMedica And 2 Other Penny Stocks Insiders Are Buying

    4/3/24 9:13:02 AM ET
    $CALC
    $RCG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance
    Get the next $CALC alert in real time by email

    The Dow Jones index closed lower by around 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    CalciMedica

    • The Trade: CalciMedica, Inc. (NASDAQ:CALC) Chief Business Officer Eric W Roberts acquired a total of 4,000 shares an average price of $3.90. To acquire these shares, it cost around $15,600.
    • What’s Happening: On March 28, CalciMedica posted a fourth-quarter loss of 23 cents per share.
    • What CalciMedica Does: CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need.

    Tecogen

    • The Trade: Tecogen Inc. (OTC:TGEN) Director John Hatsopoulos acquired a total of 30,000 shares at at an average price of $0.70. To acquire these shares, it cost around $7,000.
    • What’s Happening: On March 13, Tecogen reported revenues of $5.9 million and a net loss of $1.8 million for the quarter ended Dec. 31, 2023.
    • What Tecogen Does: Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production.

    Check This Out: Acuity Brands Likely To Report Higher Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

    RENN Fund

    • The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 57 shares at an average price of $1.56. The insider spent around $89 to buy those shares.
    • What’s Happening: RENN Fund shares gained 5% over the past month.
    • What RENN Fund Does: RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments.

     

    Don’t forget to check out our premarket coverage here

    Get the next $CALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALC
    $RCG

    CompanyDatePrice TargetRatingAnalyst
    CalciMedica Inc.
    $CALC
    1/29/2026Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $CALC
    $RCG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $RCG
    SEC Filings

    View All

    SEC Form N-CSR filed by RENN Fund Inc

    N-CSR - RENN Fund, Inc. (0000919567) (Filer)

    3/9/26 4:07:11 PM ET
    $RCG
    Investment Managers
    Finance

    SEC Form S-3 filed by CalciMedica Inc.

    S-3 - CalciMedica, Inc. (0001534133) (Filer)

    3/3/26 4:54:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by CalciMedica Inc.

    10-K - CalciMedica, Inc. (0001534133) (Filer)

    3/3/26 4:05:57 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $RCG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

    Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 LA JOLLA, Calif., March 3, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic

    3/3/26 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

    Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population char

    1/28/26 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025

    11/12/25 7:01:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $RCG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/Co-Portfolio Manager Stahl Murray bought $3,345 worth of shares (1,134 units at $2.95), increasing direct ownership by 0.24% to 153,494 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/10/26 11:29:29 AM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,323 worth of shares (1,134 units at $2.93), increasing direct ownership by 0.24% to 153,134 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/9/26 11:02:32 AM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,289 worth of shares (1,134 units at $2.90), increasing direct ownership by 0.24% to 152,774 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/6/26 1:09:50 PM ET
    $RCG
    Investment Managers
    Finance

    $CALC
    $RCG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/Co-Portfolio Manager Stahl Murray bought $3,345 worth of shares (1,134 units at $2.95), increasing direct ownership by 0.24% to 153,494 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/10/26 11:29:29 AM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,323 worth of shares (1,134 units at $2.93), increasing direct ownership by 0.24% to 153,134 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/9/26 11:02:32 AM ET
    $RCG
    Investment Managers
    Finance

    President/Co-Portfolio Manager Stahl Murray bought $3,289 worth of shares (1,134 units at $2.90), increasing direct ownership by 0.24% to 152,774 units (SEC Form 4)

    4 - RENN Fund, Inc. (0000919567) (Issuer)

    3/6/26 1:09:50 PM ET
    $RCG
    Investment Managers
    Finance

    $CALC
    $RCG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 3:32:39 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 1:05:20 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $RCG
    Financials

    Live finance-specific insights

    View All

    FRMO Corp. Announces Fiscal 2025 Second Quarter Results, Conference Call, and New Board Appointment

    FRMO Corp. (the "Company" or "FRMO") (OTC:FRMO) today reported its financial results for the 2025 second quarter ended November 30, 2024. Financial Highlights FRMO's total book value as of November 30, 2024 was $821.4 million ($18.66 per share on a fully diluted basis), including $407.8 million of non-controlling interests. Excluding the non-controlling interests, book value was $413.6 million ($9.39 per share). This compares with total book value at the prior fiscal year end on May 31, 2024 of $403.3 million ($9.16 per share), including $161.1 million of non-controlling interests. Excluding the non-controlling interests, book value was $242.1 million ($5.50 per share). Current assets

    1/14/25 7:55:00 PM ET
    $RCG
    Investment Managers
    Finance

    CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

    Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

    10/30/24 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

    Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

    10/28/24 4:05:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    $RCG
    Leadership Updates

    Live Leadership Updates

    View All

    CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    5/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    3/27/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

    LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

    1/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care